CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
erlotinib and bexarotenedrug
Likely dose
Erlotinib 150 mg orally daily and bexarotene 400 mg orally dailyAI-extracted
Key inclusion· 1
  • ✓Advanced non-small cell lung cancer
Key exclusion· 1
  • ✕Hepatic or renal dysfunction

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00125359
NCT00125359Phase 2Completed
CompareCT.gov

A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-small Cell Lung Cancer

Konstantin Dragnev·interventional·Posted Aug 1, 2005·Updated Jan 8, 2019

In Brief

A Phase 2 clinical trial evaluating erlotinib and bexarotene for Carcinoma, Non-small-cell Lung. Completed, enrolled 42 participants across 2 sites.

Detailed Summary

The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer. Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-small-cell Lung
CountriesUnited States
CollaboratorsLigand Pharmaceuticals, Genentech, Inc.

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 1, 2005
Enrollment StartAug 1, 2005
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 20.9 years ago

Interventions

erlotinib and bexarotenedrug

Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.